Company intelligence / Profile preview

CarpoNovum

Ownership: Private
Employees: ~10
Development stage: Other

Overview

CarpoNovum has developed the C‑REX® family of surgical instruments for colorectal surgery, with CE marking achieved in 2018/2019. Clinical studies have been conducted in Sweden, Denmark, and China. A recent investigator‑initiated study was successfully finalized in Malmö, Sweden in 2023. The primary focus is on improving outcomes of colorectal anastomoses by reducing leak rates and enhancing healing.

Therapeutic areas: Oncology
Modalities: Device
Industry: Surgical Medical Devices

Beyond the preview

Go deeper on CarpoNovum.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CarpoNovum.

Explore the full profile